There has been much hype and controversy over the so-called 'Noakes' diet. This diet advocates a low-cardohydrate, highfat and high-protein intake. As previously reported in the Journal, Noakes has expressed the view that this diet coupled with exercise could have a favourable impact on lipid levels and potentially avoid the need for drug therapy.
1 In that same report, it was noted that this has not been subjected to scientific validation. More recently the ability of the Noakes diet to give better weight-control results than a 'balanced diet' has been questioned.
2
I have recently seen a patient who had been diagnosed with dyslipidaemia several years ago and was receiving rosuvastatin 5 mg daily. A lipogram taken in April 2012 (on therapy) showed a total cholesterol (TC) level of 5.1 mmol/l and low-density lipoprotein cholesterol (LDL-C) of 2.9 mmol/l, respectively. After two months on the Noakes diet, she had the lipogram repeated. This now showed a TC of 12.9 mmol/l and LDL-C of 9.6 mmol/l, respectively. This was in the absence of diabetes mellitus and hypothyroidism.
While one case does not make a scientific study, it should nevertheless alert practitioners involved in treating patients with dyslipidaemia and attempting to lower cardiovascular risk, that subjects on the Noakes diet should be cautioned as to the potential risks and have their lipid profiles closely monitored. 
industry News Cipla medpro wins r280-million state therapeutic drugs tender
Cipla Medpro, the third largest pharmaceutical company in South Africa, today announced that it has been awarded a R280 million share of the South African Government's national solid-dose tender to supply therapeutic drugs. The contract is effective from 1 August 2014 and will run for a period of two years. According to Cipla Medpro, the majority of products to be supplied will be in the mental health, cardiovascular and women's health categories. Paul Miller, CEO of Cipla Medpro, says that the company has for many years been providing the private market with high-quality products, and is now committed to supporting Government by providing all South Africans with high-quality and affordable medicine. 'With our country's evolving healthcare environment, Government has clearly identified a growing need for therapeutic drugs in the mental health, cardiovascular and women's health arenas, and we remain committed to supporting them in these much-needed therapeutic drug categories.'
Miller points to Health Minister, Dr Aaron Motsoaledi's recent Health Budget speech, which highlighted the need to tackle mental health and women's health challenges in South Africa. 'With this contract, Cipla will now be assisting Government with its National Development Plan goals which include, among others, reducing the burden of non-communicable diseases such as mental health among everyday South Africans, as well as reducing maternal deaths and improving women's health by tackling diseases such as hypertension. ' This latest Government tender win is the third in the space of less than two years for the growing pharmaceutical company, and follows Cipla Medpro winning a R345 million national respiratory tender (June 2014) and an antiretroviral tender valued at approximately R1.448 billion (November 2012).
'We are extremely proud to have won this tender which is not only testament to our high-quality product portfolio, but is also in line with Cipla's ethos of advancing healthcare for all South Africans', concludes Miller.
